ReviewImmunity · 1 Feb 2024
Thymosin alpha-1: over 11,000 people in trials support its profile
A review of more than 30 clinical trials describes it as a well-tolerated immune modulator.
Thymosin alpha-1 is a thymic peptide involved in T-lymphocyte maturation and function. This review gathered more than 30 clinical trials with over 11,000 people, in areas such as COVID-19, autoimmune disease and cancer.
On that evidence, the authors describe it as a well-tolerated and effective immune modulator. Some results vary by disease, and in sepsis a large recent trial showed no mortality benefit.
In three points
- Review of 30+ trials with over 11,000 people
- Favourable safety profile
- Results vary by the disease studied
PubMed · International Immunopharmacology
Plain-language summary by SYNTRA LABS based on the original publication and checked against its source. It is not medical advice or a recommendation for use. SYNTRA LABS compounds are for research use only and not for human consumption.